Antibiotic Resistance among Gram-Negative Bacilli in US Intensive Care Units: Implications for Fluoroquinolone Use

JAMA

Volumn 289, Issue 7, 2003, Pages 885-888

  Neuhauser, Melinda M ^a   Weinstein, Robert A ^b,c   Rydman, Robert ^c,d   Danziger, Larry H ^d   Karam, George ^e   Quinn, John P ^b,c  

^a UNIVERSITY OF HOUSTON   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c Jr Hospital of Cook County   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TICARCILLIN; TIMENTIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

AEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG USE; ENTEROBACTER; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; INCIDENCE; INTENSIVE CARE UNIT; KLEBSIELLA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS; CLINICAL TRIAL; CROSS INFECTION; DRUG EFFECT; DRUG UTILIZATION; GRAM NEGATIVE INFECTION; HUMAN; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTICENTER STUDY; STATISTICS; UNITED STATES;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; UNITED STATES;

EID: 0037453976     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.7.885     Document Type: Article

References (16)

1. Archibald L, Phillips L, Monnet D, McGowan JE, Tenover F, Gaynes R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis. 1997;24:211-215.
2. Fridkin SK, Steward CD, Edwards JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Clin Infect Dis. 1999;29:245-252.
3. Itokazu GS, Quinn JP, Bell-Dixon C, Kahan FM, Weinstein RA. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin Infect Dis. 1996;23:779-784.
4. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characteristics of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis. 2001;32:S146-S155.
5. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial blood-stream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999;29:239-244.
6. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-April 2000, issued June 2000. Am J Infect Control. 2000;28:429-448.
7. Tankovic J, Bachoual R, Ouabdesselam S, Boudjadja A, Soussy CJ. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis. J Antimicrob Chemother. 1999;43(suppl B):S19-S23.
8. Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA. 1999;281:517-523.
9. Paterson DL, Mulazimoglu L, Casellas JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamases production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis. 2000;30:473-478.
10. Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet. 1998;351:797-799.
11. Kohler T, Epp SF, Curty LK, Pechere JC. Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol. 1999;181:6300-6305.
12. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis. 2001;33:1288-1294.
13. Walson JL, Marshall B, Pokhrel BM, Kafle KK, Levy SB. Carriage of antibiotic-resistant fecal bacteria in Nepal reflects proximity to Kathmandu. J Infect Dis. 2001;184:1163-1169.
14. Hanberger H, Garcia-Rodrigues JA, Gobernado M, et al. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. JAMA. 1999;281:67-71.
15. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis. 2000;31:S24-S28.
16. Gonzales R, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: background, specific aims, and methods. Ann Intern Med. 2001;134:479-486.